525 papers found
Refreshing results…
Abstract 4524: Comparison of PDX, PDC, and PDOrg models from the National Cancer Institute’s Patient-Derived Models Repository (PDMR)
Abstract LB-293: A Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed metastatic colorectal carcinoma
Introduction by the Guest Editor
Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers
Abstract 5240: Long-term treatment with IL-4, IL-6, and/or IL-17 increases the expression of the NADPH oxidase DUOX2 in human colon cancer cells in vitro
Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib)
RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB
Integrative analyses of signaling and DNA damage repair pathways in patient-derived xenograft (PDX) models from NCI’s patient-derived models repository (PDMR).
Measuring phospho-MET by multiplex immunofluorescence to aid in selection of patients with MET activation in tumors.
Trial in progress abstract phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.
Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.
Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.
Development and analytical validation of a 523-gene clinical assay for cell-free DNA.
Pharmacodynamics of PI3K, MEK, and AKT inhibitors through isoform-specific measurements of MEK, ERK, AKT, and ribosomal protein S6 in needle biopsies.
A multiplex immunofluorescence assay to assess immune checkpoint inhibitor-targeted CD8 activation and tumor colocalization in FFPE tissues.
Exposure time versus cytotoxicity for anticancer agents
Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers
Modernizing Clinical Trials for Patients With Cancer
Guidelines for the Detection of NADPH Oxidases by Immunoblot and RT-qPCR
Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins
Missing publications? Read more about our data sources.